Exicure, Inc. (XCUR) Stock Analysis & Investment Frameworks
Exicure, Inc. (XCUR) stock analysis on Invetso. Review Exicure, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Exicure, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Exicure, Inc. Key Financial Metrics
- Market Cap: $6.61M
- Revenue: $N/A
- ROE: -237.91%
- ROIC: -93.88%
- Dividend Yield: N/A
About Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure, Inc. Investment Frameworks
Invetso analyzes Exicure, Inc. (XCUR) across the following frameworks:
- Exicure, Inc. 10Y Growth Potential
- Exicure, Inc. Scenario Analysis
- Exicure, Inc. Risks & Opportunities
- Exicure, Inc. Economic Moat
- Exicure, Inc. Business Model
- Exicure, Inc. Management
- Exicure, Inc. SWOT Analysis
- Exicure, Inc. Porter's 5 Forces
- Exicure, Inc. PESTLE Analysis
- Exicure, Inc. ESG Analysis